Rifampicin-induced lupus erythematosus

Patel, Girish Khandubhai; Anstey, Alexander Vincent

doi:10.1046/j.1365-2230.2001.00809.x

Cited by 28 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both environmental, such as certain drugs or viruses, and genetic factors are involved in the development of the disease. 1,2 The mode of inheritance is unknown, but both familial aggregation and twin studies support a strong genetic component for SLE: the concordance ratio of affected monozygotic twins over dizygotic twins is 10-fold (420 vs 2%) and the risk for a first-degree relative is 10 -20 times higher compared to the general population. 3,4 Several candidate loci (including the HLA region, Fcg receptors, complement components and recently programmed cell death 1 gene (PDCD1) have been implicated through association studies and candidate susceptibility loci have been detected on inbred mouse models of SLE.…”

Section: Introductionmentioning

confidence: 99%

Haplotype associations define target regions for susceptibility loci in systemic lupus erythematosus

Koskenmies

Widén²,

Onkamo

et al. 2004

Eur J Hum Genet

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by diverse and variable clinical manifestations. The etiology of SLE is still unknown, but both environmental and genetic factors are involved. Recent genome-wide scans and candidate genes studies in different ethnic groups have already suggested susceptibility loci for SLE, but most of the genetic component remains unexplained. We have previously conducted a genome-wide scan in 35 Finnish families multiply affected with SLE. With 417 microsatellite markers, we detected suggestive linkage in regions on chromosomes 6q and 14q as well as HLA on 6p. The 14q locus has also been implicated in three previous genome scans on SLE, whereas a partially overlapping region on 6q was implicated in one previous study. In an effort to obtain additional evidence for susceptibility loci on 6q and 14q and in order to refine their positions, we performed fine mapping at 1 cM density across the suggestive regions of linkage. Our results show evidence for excess sharing of a haplotype on 14q and excess transmission of a haplotype on 6q. Our results are compatible with the idea of a founder effect for susceptibility genes in SLE in central eastern Finland and suggest a path to the isolation of the putative susceptibility genes.

show abstract

Section: Introductionmentioning

confidence: 99%

Haplotype associations define target regions for susceptibility loci in systemic lupus erythematosus

Koskenmies

Widén²,

Onkamo

et al. 2004

Eur J Hum Genet

View full text Add to dashboard Cite

show abstract

“…12,13,14 None of them had any family history of similar illness. 15,16 There were no history of any precipitating drugs or infection in contrary to many studies, which purpose roles of infection, 2,17 stress and triggering drugs 18,19,20,21 in initiating autoreactivity. In our study, majority of patients had SLE (62.5%) compared to DLE (37.5%).…”

Section: Discussionmentioning

confidence: 94%

A Clinical Study of the Cutaneous Manifestations of Lupus Erythematosus

Issac¹,

Sobhanakumari²,

Surabhi³

et al. 2017

jebmh

View full text Add to dashboard Cite

BACKGROUND Lupus Erythematosus (LE) is a group of heterogenous autoimmune diseases with an array of manifestations ranging from cutaneous lesions to life-threatening systemic manifestations. Cutaneous manifestations are the second most common feature and it serves as an important diagnostic aid. The nonspecific skin lesions are associated with more active disease. The aim of the study is to study the pattern and prevalence of cutaneous manifestations in LE and to study the correlation between cutaneous manifestations and systemic involvement. MATERIALS AND METHODS Study comprised of 48 patients of lupus erythematosus who attended the Department of Dermatology and Venereology in a tertiary referral centre from a period of November 2010 to November 2012. Patients were subjected to detailed clinical examination, routine investigations, ANA, anti-dsDNA, ANA profile, non-lesional skin biopsy for lupus band test. RESULTS 48 patients were taken for the study. The peak incidence was in the age group of 30-40 (33.33%) yrs. There was female predominance, the ratio being 5.86:1. Discoid Lupus Erythematosus (DLE) constitutes 37.5% and Systemic Lupus Erythematosus (SLE) 62.5%. Majority of DLE patients (38.89%) presented late in 5-9 yrs., whereas SLE patients presented early within 1-6 months (50%). Most frequent presenting features were arthralgia (54.17%), oral ulcers (45.83%). Renal system was the most common system affected (16.67%). Most common haematological abnormality was anaemia and raised ESR (40%). Most common immunological abnormality was raised ANA in 66.7% and raised anti-dsDNA (60%). Most frequent biochemical abnormality was albuminuria and raised 24-hours urine protein. Lupus band was positive in 58.33% and all had renal involvement. Mortality was 6.67%. CONCLUSION In this study, we got comparable results in epidemiological parameters like age and distribution with other studies. The incidence of ANA negative SLE was higher (33.33%) in our study. Though majority of patients with renal involvement had a positive lupus band test, a statistical significance could not be sought in this regard on account of low sample size.

show abstract

“…Although we did not observe positive serum antihistone antibodies, these can be negative in as many as a quarter of DIL cases [ 9 ]. While DIL is occasionally associated with rifampin, the resolution of symptoms in the case despite continued exposure to this agent argues that it did not play a role [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

A patient on RIPE therapy presenting with recurrent isoniazid-associated pleural effusions: a case report

Varenika

Blanc

2011

J Med Case Reports

View full text Add to dashboard Cite

IntroductionThe clinical scenario of a new or worsening pleural effusion following the initiation of antituberculous therapy has been classically referred to as a 'paradoxical' pleural response, presumably explained by an immunological rebound phenomenon. Emerging evidence suggests that there also may be a role for a lupus-related reaction in the pathophysiology of this disorder.Case presentationAn 84-year-old Asian man treated with isoniazid, along with rifampin, pyrazinamide and ethambutol for suspected extrapulmonary tuberculosis, presented with a recurrent pleural effusion, his third episode since the initiation of this therapy. The first effusion occurred one month after the start of treatment, without any prior evidence of pulmonary tuberculosis involvement. Follow-up testing, including thoracoscopic pleural biopsies, never confirmed tuberculosis infection. Further evaluation yielded serological evidence suggesting drug-induced lupus. No effusions recurred following the discontinuation of isoniazid, although other antituberculosis medications were continued.ConclusionThe immunological rebound construct is inconsistent with the evolution of this case, which indicates rather that drug-induced lupus may explain at least some cases of new pleural effusions following the initiation of isoniazid.

show abstract

Rifampicin-induced lupus erythematosus

Cited by 28 publications

References 15 publications

Haplotype associations define target regions for susceptibility loci in systemic lupus erythematosus

Haplotype associations define target regions for susceptibility loci in systemic lupus erythematosus

A Clinical Study of the Cutaneous Manifestations of Lupus Erythematosus

A patient on RIPE therapy presenting with recurrent isoniazid-associated pleural effusions: a case report

Contact Info

Product

Resources

About